GE HealthCare Raises 2026 Revenue Guidance Amid Strong Backlog and Margin Expansion
GE HealthCare (GEHC) has raised its full-year 2026 organic revenue guidance to 4% following a strong third quarter characterized by 6.2% organic revenue growth. The company reported a significant equipment backlog of $23.7 billion, representing a 12% year-over-year increase driven by high demand for advanced imaging equipment and diagnostic drugs. Management is focusing on long-term stability through three strategic pillars: leveraging the recurring revenue from its Pharmaceutical Diagnostics division, implementing the 'Heartbeat' operating system to streamline manufacturing, and securing multiyear supply agreements for critical memory chips. These initiatives aim to protect production schedules against component shortages and drive operational efficiency as the company scales.
Tickers: $GEHC
Topics: backlog growth earnings report pharmaceutical diagnostics revenue guidance